Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; 15 of the 21 sources its claims cite were checked for support.

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

Open access

Abstract

Obesity is a major public health crisis. Multi-specific peptides have emerged as promising therapeutic strategies for clinical weight loss. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are endogenous incretins that regulate weight through their receptors (R). AMG 133 (maridebart cafraglutide) is a bispecific molecule engineered by conjugating a fully human monoclonal anti-human GIPR antagonist antibody to two GLP-1 analogue agonist peptides using amino acid linkers. Here, we confirm the GIPR antagonist and GLP-1R agonist activities in cell-based systems and report the ability of AMG 133 to reduce body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. In a phase 1, randomized, double-blind, placebo-controlled clinical study in participants with obesity ( NCT04478708 ), AMG 133 had an acceptable safety and tolerability profile along with pronounced dose-dependent weight loss. In the multiple ascending dose cohorts, weight loss was maintained for up to 150 days after the last dose. These findings support continued clinical evaluation of AMG 133.

Overview

CoChat Summary

TL;DR

AMG 133 (maridebart cafraglutide), a bispecific GLP-1R agonist/GIPR antagonist, reduced body weight and improved metabolic markers in preclinical models and showed dose-dependent weight loss with acceptable safety in a phase 1 obesity study. In the multiple ascending dose (MAD) cohorts, weight loss persisted up to 150 days after the last dose.

Key findings

  • In cell-based assays, AMG 133 antagonized native GIP at human GIPR with an IC50 of 42.4 nM and at cynomolgus monkey GIPR with an IC50 of 26.5 nM; it also agonized human GLP-1R with an EC50 of 24.4 pM.
  • In male obese mice, the AMG 133 murine surrogate reduced body weight, food intake, blood glucose, plasma insulin, and lipid levels; in one db/db mouse study, maximal body-weight loss occurred within 24 h and remained significant up to 216 h after injection.
  • In obese cynomolgus monkeys, weekly s.c. dosing for 6 weeks reduced body weight by 11% at 0.25 mg kg−1 and 13% at 0.75 mg kg−1, with reductions in total energy intake, fasting triglycerides, fasting insulin, total cholesterol, and LDL-C.
  • In the phase 1 study, 49 participants were enrolled into SAD cohorts and 26 into MAD cohorts; in MAD, the 420 mg Q4W group had a mean body-weight change of −14.5% by day 85, and weight loss in that group remained up to −11.2% at 150 days after the last dose.

Methods

  • Preclinical program: in vitro receptor assays plus PK/pharmacology studies in male mice (including db/db and DIO models) and obese cynomolgus monkeys; analyses included body weight, food intake, glucose, insulin, and lipid measurements.
  • Phase 1 program: first-in-human, double-blind, randomized, placebo-controlled study (NCT04478708) with SAD and MAD cohorts in adults with obesity; 75 participants were in the final reported SAD/MAD dataset.
  • Main analyses were descriptive for the clinical study (PK/PD/safety), with PK estimated by noncompartmental analysis; animal studies used ANOVA/mixed-effects methods with multiple-comparison testing.

Limitations

  • The paper states the main limitation of the first-in-human study was the small sample size, requiring cautious interpretation of PD effects and metabolic parameters.
  • The participants had neither diabetes nor high triglyceride/cholesterol levels, which the paper says limits generalizability of metabolic findings.
  • The study had no active comparator arm, and the human trial design could not separate the individual contributions of GIPR antagonism versus GLP-1 agonism to weight loss.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s42255-023-00966-w

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 AMG 133 exhibited GIPR antagonist and GLP-1R agonist activities in vitro and extended PK profiles. a, Structure of AMG 133. The GLP-1 analogue peptide sequence is H[Aib]EGTFTSDYSSYLEEQAAKEFIAWLVKGGG(GGGGS)3 K(BrAc){CONH2}. b, In vitro potency of AMG 133. c–e, PK properties after a single dose of 5 mg kg−1 i.v. administration of AMG 133 to CD-1 mice (c), a single dose of 3 mg kg−1 s.c. administration of AMG 133 to female cynomolgus monkeys (d) and s.c. administration of AMG 133 to obese male cynomolgus monkeys (e). AUC, area under the curve; AUCinf, AUC zero to infinity; Vss, volume in steady state; CL, clearance; F, fraction absorbed; EC50, half maximal effective concentration; GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP-1R, glucagon-like peptide-1 receptor; IC50, half maximal inhibitory concentration; IV, intravenous; PK, pharmacokinetic; SC, subcutaneous; tmax, time of maximum observed concentration.
Fig. 1 AMG 133 exhibited GIPR antagonist and GLP-1R agonist activities in vitro and extended PK profiles. a, Structure of AMG 133. The GLP-1 analogue peptide sequence is H[Aib]EGTFTSDYSSYLEEQAAKEFIAWLVKGGG(GGGGS)3 K(BrAc){CONH2}. b, In vitro potency of AMG 133. c–e, PK properties after a single dose of 5 mg kg−1 i.v. administration of AMG 133 to CD-1 mice (c), a single dose of 3 mg kg−1 s.c. administration of AMG 133 to female cynomolgus monkeys (d) and s.c. administration of AMG 133 to obese male cynomolgus monkeys (e). AUC, area under the curve; AUCinf, AUC zero to infinity; Vss, volume in steady state; CL, clearance; F, fraction absorbed; EC50, half maximal effective concentration; GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP-1R, glucagon-like peptide-1 receptor; IC50, half maximal inhibitory concentration; IV, intravenous; PK, pharmacokinetic; SC, subcutaneous; tmax, time of maximum observed concentration.CC BY · PubMed Central
Fig. 2 AMG 133 murine surrogate reduced body weight in mouse models of obesity. a,b, Changes in BW (a) and blood glucose (b) in male db/db mice following a single i.p. injection of the AMG 133 murine surrogate; n = 8 per group. c–h, Dose-dependent reductions in BW (c) and food intake (d) with the AMG 133 murine surrogate in DIO mice. Blood glucose (e), fasting insulin (f), triglycerides (g) and total cholesterol (h) decreased in DIO mice treated with the AMG 133 murine surrogate. **P < 0.01, ***P < 0.001 and ****P < 0.0001 versus vehicle (a–c) or versus vehicle and between doses (d–h). NS, not significant. +P < 0.05, ++P < 0.01 and +++P < 0.001 between doses (c). Data represent group mean ± s.e.m. n = 5–8 per group depending on group and dataset. Statistical tests were all adjusted for multiple comparisons and included two-way analysis of variance (ANOVA) (a–c), mixed-effects analysis (d) and ordinary one-way ANOVA (e–h). Source data
Fig. 2 AMG 133 murine surrogate reduced body weight in mouse models of obesity. a,b, Changes in BW (a) and blood glucose (b) in male db/db mice following a single i.p. injection of the AMG 133 murine surrogate; n = 8 per group. c–h, Dose-dependent reductions in BW (c) and food intake (d) with the AMG 133 murine surrogate in DIO mice. Blood glucose (e), fasting insulin (f), triglycerides (g) and total cholesterol (h) decreased in DIO mice treated with the AMG 133 murine surrogate. **P < 0.01, ***P < 0.001 and ****P < 0.0001 versus vehicle (a–c) or versus vehicle and between doses (d–h). NS, not significant. +P < 0.05, ++P < 0.01 and +++P < 0.001 between doses (c). Data represent group mean ± s.e.m. n = 5–8 per group depending on group and dataset. Statistical tests were all adjusted for multiple comparisons and included two-way analysis of variance (ANOVA) (a–c), mixed-effects analysis (d) and ordinary one-way ANOVA (e–h). Source dataCC BY · PubMed Central
Fig. 3 AMG 133 reduced body weight in obese cynomolgus monkeys. a–e, AMG 133 led to a reduction in BW (a), total energy intake (TEI) (b), triglycerides (c), fasting insulin (d), total cholesterol (e) and LDL-C (f). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 versus vehicle. +P < 0.05 for AMG 133 0.25 mg kg−1 versus AMG 133 0.75 mg kg−1. Data show group mean ± s.e.m.; vehicle n = 10, AMG 133 0.25 mg kg−1 n = 9 and AMG 133 0.75 mg kg−1 n = 8. Statistical test used was a two-way ANOVA adjusted for multiple comparisons (a,c–f; statistical analysis not performed on TEI). Source data
Fig. 3 AMG 133 reduced body weight in obese cynomolgus monkeys. a–e, AMG 133 led to a reduction in BW (a), total energy intake (TEI) (b), triglycerides (c), fasting insulin (d), total cholesterol (e) and LDL-C (f). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 versus vehicle. +P < 0.05 for AMG 133 0.25 mg kg−1 versus AMG 133 0.75 mg kg−1. Data show group mean ± s.e.m.; vehicle n = 10, AMG 133 0.25 mg kg−1 n = 9 and AMG 133 0.75 mg kg−1 n = 8. Statistical test used was a two-way ANOVA adjusted for multiple comparisons (a,c–f; statistical analysis not performed on TEI). Source dataCC BY · PubMed Central
Fig. 4 Clinical PK and PD profiles of AMG 133 in humans. a, AMG 133 PK parameters; tmax is presented as the median and t1/2 is presented as the geometric mean. AUC0–28 is presented as the geometric mean (CV%) after the last dose of AMG 133 on day 57 for MAD cohorts. b–e, Mean (s.e.m.) percent change from baseline in BW after single doses, n = 6–7 for AMG 133 and n = 12 for placebo at day 1 (b) and multiple doses, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (c). Mean (s.e.m.) change from baseline in BMI, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (d) and waist circumference, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (e) after multiple doses of AMG 133. Arrows indicate when the investigational product was administered: at day 1 in the SAD cohorts (b) and at day 1, 29 and 57 in the MAD cohorts (c–e). Source data
Fig. 4 Clinical PK and PD profiles of AMG 133 in humans. a, AMG 133 PK parameters; tmax is presented as the median and t1/2 is presented as the geometric mean. AUC0–28 is presented as the geometric mean (CV%) after the last dose of AMG 133 on day 57 for MAD cohorts. b–e, Mean (s.e.m.) percent change from baseline in BW after single doses, n = 6–7 for AMG 133 and n = 12 for placebo at day 1 (b) and multiple doses, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (c). Mean (s.e.m.) change from baseline in BMI, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (d) and waist circumference, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (e) after multiple doses of AMG 133. Arrows indicate when the investigational product was administered: at day 1 in the SAD cohorts (b) and at day 1, 29 and 57 in the MAD cohorts (c–e). Source dataCC BY · PubMed Central
Fig. 5 Changes in metabolic and inflammatory parameters in humans with multiple ascending doses of AMG 133. a–f, Mean (s.e.m.) change from baseline in fasting glucose, n = 5–8 for AMG 133 and n = 6 for placebo at day 1 (a), fasting insulin, n = 4–8 for AMG 133 and n = 5 for placebo at day 1 (b), fasting C-peptide n = 3–8 for AMG 133 and n = 5 for placebo at day 1 (c), fasting glucagon, n = 3–8 for AMG 133 and n = 5 for placebo at day 1 (d), HbA1c, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (e) and hs-CRP, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (f) after MADs of AMG 133. Arrows indicate when the investigational product was administered at day 1, 29 and 57. Source data
Fig. 5 Changes in metabolic and inflammatory parameters in humans with multiple ascending doses of AMG 133. a–f, Mean (s.e.m.) change from baseline in fasting glucose, n = 5–8 for AMG 133 and n = 6 for placebo at day 1 (a), fasting insulin, n = 4–8 for AMG 133 and n = 5 for placebo at day 1 (b), fasting C-peptide n = 3–8 for AMG 133 and n = 5 for placebo at day 1 (c), fasting glucagon, n = 3–8 for AMG 133 and n = 5 for placebo at day 1 (d), HbA1c, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (e) and hs-CRP, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (f) after MADs of AMG 133. Arrows indicate when the investigational product was administered at day 1, 29 and 57. Source dataCC BY · PubMed Central
Extended Data Fig. 1 Conjugation of GLP-1 peptide analog to GIPR antibody. AMG 133 chemical structure.
Extended Data Fig. 1 Conjugation of GLP-1 peptide analog to GIPR antibody. AMG 133 chemical structure.CC BY · PubMed Central
Extended Data Fig. 2 In vitro functional activity of AMG 133 or AMG 133 murine surrogate. (a–d) Representative dose-response curves of cAMP assays in cells expressing human GIPR (A), human GLP-1R (B), mouse GIPR (C), or mouse GLP-1R (D). 50 pM or 90 pM GIP was used in the antagonist mode (A&C) of the assay. Data are represented as mean ± SEM of n = 2 replicates per treatment. Source data
Extended Data Fig. 2 In vitro functional activity of AMG 133 or AMG 133 murine surrogate. (a–d) Representative dose-response curves of cAMP assays in cells expressing human GIPR (A), human GLP-1R (B), mouse GIPR (C), or mouse GLP-1R (D). 50 pM or 90 pM GIP was used in the antagonist mode (A&C) of the assay. Data are represented as mean ± SEM of n = 2 replicates per treatment. Source dataCC BY · PubMed Central
Extended Data Fig. 3 Phase 1 trial patient disposition. (a) SAD participant flow chart (CONSORT diagram). (b) MAD participant flow chart (CONSORT diagram).
Extended Data Fig. 3 Phase 1 trial patient disposition. (a) SAD participant flow chart (CONSORT diagram). (b) MAD participant flow chart (CONSORT diagram).CC BY · PubMed Central
Extended Data Fig. 4 Changes in free fatty acids and lipid parameters in humans with multiple ascending doses of AMG 133. (a–d) Mean (SE) change from baseline in fasting free fatty acids, n = 6–8 for AMG 133 and n = 6 for placebo at Day 1 (A), fasting triglycerides, n = 6 for AMG 133 and n = 6 for placebo at Day 1 (B), fasting total cholesterol, n = 6–8 for AMG 133 and n = 6 for placebo at Day 1 (C), fasting LDL, n = 6 for AMG 133 and n = 6 for placebo at Day 1 (D) after multiple ascending doses of AMG 133 or placebo. Arrows indicate when the investigational product was administrated: at day 1, 29, and 57. Source data
Extended Data Fig. 4 Changes in free fatty acids and lipid parameters in humans with multiple ascending doses of AMG 133. (a–d) Mean (SE) change from baseline in fasting free fatty acids, n = 6–8 for AMG 133 and n = 6 for placebo at Day 1 (A), fasting triglycerides, n = 6 for AMG 133 and n = 6 for placebo at Day 1 (B), fasting total cholesterol, n = 6–8 for AMG 133 and n = 6 for placebo at Day 1 (C), fasting LDL, n = 6 for AMG 133 and n = 6 for placebo at Day 1 (D) after multiple ascending doses of AMG 133 or placebo. Arrows indicate when the investigational product was administrated: at day 1, 29, and 57. Source dataCC BY · PubMed Central
Extended Data Fig. 5 In vitro functional activity comparison between AMG 133 and hGIPR-Ab/P1. (a) Representative dose-response curves of cAMP assays with GIP (agonist mode) and AMG 133 or hGIPR-Ab/P1 + 50 pM GIP (antagonist mode) in cells expressing human GIPR. Data are represented as mean ± SEM of n = 2 replicates per treatment. (b) Representative dose-response curves of cAMP assays with GLP-1, AMG 133 or hGIPR-Ab/P1 in cells expressing human GLP-1R. Data are represented as mean ± SEM of n = 2 replicates per treatment. Source data
Extended Data Fig. 5 In vitro functional activity comparison between AMG 133 and hGIPR-Ab/P1. (a) Representative dose-response curves of cAMP assays with GIP (agonist mode) and AMG 133 or hGIPR-Ab/P1 + 50 pM GIP (antagonist mode) in cells expressing human GIPR. Data are represented as mean ± SEM of n = 2 replicates per treatment. (b) Representative dose-response curves of cAMP assays with GLP-1, AMG 133 or hGIPR-Ab/P1 in cells expressing human GLP-1R. Data are represented as mean ± SEM of n = 2 replicates per treatment. Source dataCC BY · PubMed Central
Extended Data Fig. 6 The HPLC-TOF-MS spectrum and SEC chromatograph of AMG 133. (a) HPLC-TOF chromatogram, UV 214 nm. (b)TOF-MS, full spectrum. (C) SEC chromatogram, UV 280 nm.
Extended Data Fig. 6 The HPLC-TOF-MS spectrum and SEC chromatograph of AMG 133. (a) HPLC-TOF chromatogram, UV 214 nm. (b)TOF-MS, full spectrum. (C) SEC chromatogram, UV 280 nm.CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 1 Not valid · 3 Not checked · 136 Own results and interpretations

71 more claims

Create a free account to see all 149 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 34
  • It may state two separate claims as one. 53

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 42 references

Cited by

See all 218

Metadata

Authors
Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., Ambhaikar, M., Sharpsten, L., Zhu, Y., Kurra, V., Jeswani, R., Oberoi, R. K., Parnes, J. R., Honarpour, N., Neutel, J., & Strande, J. L.
Affiliations
  • Amgen (United States) (US)
  • Orange County Research Center (US)
Corresponding author
Véniant, Murielle M.
Venue
Nature Metabolism
Published
2024-02-05
Volume
6
Issue
2
Pages
290-303
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4391533080
Cited by
218
References
42
Citations by year
2026: 72 · 2025: 91 · 2024: 55
FWCI
61.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GIP receptor antagonist, GLP-1 receptor agonists, incretins, obesity, weight loss, metabolic parameters, safety and tolerability, Macaca fascicularis, obese mice
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Humans, Male, Obesity, Peptides, Weight Loss, Mice, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. https://app.cochat.ai/papers/10.1038/s42255-023-00966-w
The paper
Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., Ambhaikar, M., Sharpsten, L., Zhu, Y., Kurra, V., Jeswani, R., Oberoi, R. K., Parnes, J. R., Honarpour, N., Neutel, J., & Strande, J. L. (2024). A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nature Metabolism. https://doi.org/10.1038/s42255-023-00966-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.